Quick Answer
Nuo Therapeutics, Inc. reported Net Income Loss of -$2.51 million for the year ending 2025.
- Nuo Therapeutics, Inc. showed a decrease of -8.1% in Net Income Loss from 2024 to 2025.
- This data is from Nuo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$5.34 million | Q2 2013: -$5.04 million | Q3 2013: -$4.98 million | Q1 2014: -$5.63 million | Q2 2014: -$11.32 million | Q3 2014: -$4.79 million | Q1 2015: $4.11 million | Q2 2015: -$870.2 thousand | Q3 2015: -$13.83 million | Q1 2016: -$4.87 million | Q2 2016: -$1.29 million | Q3 2016: -$1.92 million | Q1 2017: -$1.69 million | Q2 2017: -$3.91 million | Q3 2017: -$1.38 million | Q1 2018: -$670.2 thousand | Q2 2018: -$590.2 thousand | Q3 2018: -$649.9 thousand | Q1 2019: -$679.9 thousand | Q2 2019: -$480.3 thousand | Q3 2019: -$92.6 thousand | Q1 2020: $181.4 thousand | Q2 2020: -$22.9 thousand | Q3 2020: -$15.5 thousand | Q1 2021: -$5.7 thousand | Q2 2021: -$6.5 thousand | Q3 2021: -$6.8 thousand | Q1 2022: -$375.4 thousand | Q2 2022: -$924.1 thousand | Q3 2022: -$912.8 thousand | Q1 2023: -$855.8 thousand | Q2 2023: -$871.9 thousand | Q3 2023: -$790.6 thousand | Q1 2024: -$708.8 thousand | Q2 2024: -$540.1 thousand | Q3 2024: -$578.2 thousand | Q1 2025: -$746.1 thousand | Q2 2025: -$649.7 thousand | Q3 2025: -$537.9 thousand.
- Over the full 15 years of available data (2010 to 2025), Nuo Therapeutics, Inc.'s Net Income Loss has grown by 63.1%.
- Historical annual values: Fiscal year 2025: -$2.51 million | Fiscal year 2024: -$2.32 million | Fiscal year 2023: -$3.17 million | Fiscal year 2022: -$3.17 million | Fiscal year 2021: -$90.7 thousand | Fiscal year 2020: -$90.9 thousand | Fiscal year 2019: -$1.19 million | Fiscal year 2018: -$1.54 million | Fiscal year 2017: -$14.98 million | Fiscal year 2015: -$52.81 million | Fiscal year 2014: -$18.88 million | Fiscal year 2013: -$20.25 million | Fiscal year 2012: -$19.80 million | Fiscal year 2011: -$3.51 million | Fiscal year 2010: -$6.82 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: